In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SAFEGUARDS AGAINST OTC ZOVIRAX MISUSE

This article was originally published in The Tan Sheet

Executive Summary

SAFEGUARDS AGAINST OTC ZOVIRAX MISUSE will include specific, "easy-to-read" instructions that inform consumers of the signs and symptoms of genital herpes and that stress the "importance of appropriate continuing medical attention," Burroughs Wellcome Senior Clinical Research Scientist Gray Davis, PhD, told an FDA public hearing on the proposed Rx-to-OTC switch. Patients also will be "warned" in product labeling "not to use the medication for any purpose" other than for genital herpes, Davis said.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel